Table SV. Treatment-emergent adverse events (TEAEs) leading to study discontinuation by system organ class and preferred term in constant treatment groups from baseline until week 12, period 2 (safety analysis set)

	Ustekinumab *n* = 612; 432.9 PYE			Brodalumab 140 mg Q2W *n* = 467; 293.3 PYE			Brodalumab 210 mg Q2W *n* = 537; 415.8 PYE		
	n (%)	E	E/100 PY	*n* (%)	E	E/100 PY	*n* (%)	E	E/100 PY
All TEAEs leading to withdrawal	6 (1.0)	6	14	15 (3.2)	16	5.5	24 (4.5)	28	6.7
Cardiac disorders	0			4 (0.9)	4	1.4	3 (0.6)	3	0.7
Angina unstable	0			1 (0.2)	1	0.3	1 (0.2)	1	0.2
Acute myocardial infarction	0			0			1 (0.2)	1	0.2
Angina pectoris	0			1 (0.2)	1	0.3	0		
Arrhythmia	0			1 (0.2)	1	0.3	0		
Cardiac failure	0			0			1 (0.2)	1	0.2
Myocardial infarction	0			1 (0.2)	1	0.3	0		
Gastrointestinal disorders	0			3 (0.6)	3	1.0	3 (0.6)	3	0.7
Colitis ulcerative	0			0			1 (0.2)	1	0.2
Gastritis	0			0			1 (0.2)	1	0.2
Gastroenteritis eosinophilic	0			1 (0.2)	1	0.3	0		
Oesophagitis	0			1 (0.2)	1	0.3	0		
Pancreatitis acute	0			1 (0.2)	1	0.3	0		
Upper gastrointestinal haemorrhage	0			0			1 (0.2)	1	0.2
Infections and infestations	1 (0.2)	1	0.2	0			5 (0.9)	5	1.2
Appendicitis	0			0			1 (0.2)	1	0.2
Hepatitis B	0			0			1 (0.2)	1	0.2
Meningitis cryptococcal	0			0			1 (0.2)	1	0.2
Oesophageal candidiasis	0			0			1 (0.2)	1	0.2
Oral candidiasis	1 (0.2)	1	0.2	0			0		
Staphylococcal skin infection	0			0			1 (0.2)	1	0.2
Investigations	2 (0.3)	2	0.5	2 (0.4)	2	0.7	1 (0.2)	1	0.2
Blood glucose increased	1 (0.2)	1	0.2	0			0		
Electrocardiogram QT prolonged	0			1 (0.2)	1	0.3	0		
Hepatic enzyme increased	0			0			1 (0.2)	1	0.2
Liver function test abnormal	0			1 (0.2)	1	0.3	0		
Neutrophil count abnormal	1 (0.2)	1	0.2	0			0		
Skin and subcutaneous tissue disorders	1 (0.2)	1	0.2	1 (0.2)	1	0.3	3 (0.6)	4	1.0
Psoriasis	0			0			2 (0.4)	3	0.7
Eczema	1 (0.2)	1	0.2	0			0		
Erythrodermic psoriasis	0			0			1 (0.2)	1	0.2
Urticaria	0			1 (0.2)	1	0.3	0		
Musculoskeletal and connective tissue disorders	0			3 (0.6)	4	1.4	1 (0.2)	1	0.2
Arthralgia	0			2 (0.4)	2	0.7	0		
Dactylitis	0			0			1 (0.2)	1	0.2
Joint swelling	0			1 (0.2)	1	0.3	0		
Psoriatic arthropathy	0			1 (0.2)	1	0.3	0		
Neoplasms benign, malignant and unspecified (including cysts and polyps)	1 (0.2)	1	0.2	0			2 (0.4)	2	0.5
Adenocarcinoma pancreas	0			0			1 (0.2)	1	0.2
Bladder cancer	0			0			1 (0.2)	1	0.2
Prostate cancer	1 (0.2)	1	0.2	0			0		
General disorders and administration-site conditions	1 (0.2)	1	0.2	0			1 (0.2)	1	0.2
Asthenia	1 (0.2)	1	0.2	0			0		
Influenza-like illness	0			0			1 (0.2)	1	0.2
Nervous system disorders	0			0			2 (0.4)	2	0.5
Cerebrovascular accident	0			0			1 (0.2)	1	0.2
Subarachnoid haemorrhage	0			0			1 (0.2)	1	0.2
Respiratory, thoracic and mediastinal disorders	0			1 (0.2)	1	0.3	1 (0.2)	1	0.2
Nasal discomfort	0			1 (0.2)	1	0.3	0		
Pulmonary embolism	0			0			1 (0.2)	1	0.2
Blood and lymphatic system disorders	0			1 (0.2)	1	0.3	0		
Neutropaenia	0			1 (0.2)	1	0.3	0		
Pregnancy, puerperium and perinatal conditions	0			0			1 (0.2)	1	0.2
Foetal death	0			0			1 (0.2)	1	0.2
Psychiatric disorders	0			0			1 (0.2)	2	0.5
Insomnia	0			0			1 (0.2)	1	0.2
Irritability	0			0			1 (0.2)	1	0.2
Renal and urinary disorders	0			0			1 (0.2)	1	0.2
Acute kidney injury	0			0			1 (0.2)	1	0.2
Vascular disorders	0			0			1 (0.2)	1	0.2
Deep vein thrombosis	0			0			1 (0.2)	1	0.2

E: number of events; E/100 PY: event rate per 100 patient-years; PYE: patient-years of exposure; Q2W: every 2 weeks.

Table SVI. Summary of all fatal events including patients receiving continuous and mixed treatment

Treatment at time of event	Sex/age (years)	Cause of death (PT)	Days in trial	Risk factors
Bro 210 mg Q2W	M/56	Intentional overdose (adjudicated as indeterminate)	180	Depression and substance abuse
Bro 210 mg Q2W	M/69	Oesophageal varices haemorrhage	258	(NASH-induced) liver cirrhosis; alcohol abuse
Bro 210 mg Q2W	M/52	Cardiac arrest	556	Hypercholesterolaemia
Bro 210 mg Q2W	M/70	Cerebrovascular accident		Hypertension and arrhythmia, sleep apnoea, hypothyroidism
Bro 210 mg Q2W	M/74	Sudden death	198	Coronary bypass surgery, obesity, hypercholesterolaemia, hypertension, diabetes mellitus
Bro 210 mg Q2W	M/39	Cerebral infarction	88	Upper gastrointestinal haemorrhage, alcohol abuse
Bro 210 mg Q2W	M/60	Myocardial infarction	514	Type 2 diabetes mellitus, obesity, hypertension
Bro 210 mg Q2W	M/54	Completed suicide	846	Depression
Bro 210 mg Q2W	F/24	Death (adjudicated as sudden death)	211	Cause of death undetermined
Bro 210 mg Q2W	M/39	Completed suicide	224	Legal problems
Ustekinumab	M/59	Death (adjudicated as sudden death)	140	Myocardial infarction, congestive heart failure and hypercholesterolaemia
Ustekinumab	M/60	Pancreatic carcinoma	186	High alcohol consumption, coeliac disease
Bro 210 mg Q2W	M/52	Cardiopulmonary failure	474	Hypertension, obesity and hypercholesterolaemia
Bro 210 mg Q2W	M/40	Histiocytosis haematophagic	249	Preceding infection
Bro 210 mg Q2W	M/65	Cardiac arrest	275	Type 2 diabetes mellitus, kidney stones, smoking, hypertension
Bro 210 mg Q2W	M/63	Myocardial infarction	828	Obesity, previous Myocardial infarction
Bro 140 mg Q2W	M/50	Accidental death	123	Motor vehicle accident
Bro 210 mg Q2W	M/43	Aortic aneurysm rupture	165	Type 2 diabetes mellitus

Bro: brodalumab; NASH: non-alcoholic steatohepatitis; PT: preferred term; Q2W: every 2 weeks.